Jean-Louis Dasseux, Ph.D., M.B.A.
Founder and CEO, Cerenis Therapeutics
Dr. Jean-Louis Dasseux is the founder of Cerenis and one of the world’s leading experts in lipid metabolism, lipid-protein interaction, and cardiovascular disease. With more than 30 years of experience in the pharmaceutical industry, Jean-Louis Dasseux has generated more than 85 patents families relating to HDL, RLT, the treatment of cardiovascular and metabolic diseases, and also several patents on the Cargomers® and the targeted delivery of active substances. He was the inventor of a high-capacity reverse lipid transport peptide HDL mimetic (ETC-642) and a series of small drug molecules that raise HDL levels and reduce LDL-cholesterol in the blood (Bempedoic acid currently in phase III developped by Esperion Therapeutics, and ETC-1002). He held the positions of Senior VP of Business Development and Technologies and VP of Chemistry and Technologies at Esperion Therapeutics, a company that developed the first generation of HDL mimetics (pro-apoA-I, apoA-IMilano, and apoA-I peptide) until its acquisition by Pfizer for USD 1.3 billion. Before joining Esperion, he was Research Director at Fournier, the French pharmaceutical group, where he set up and headed the research center in Heidelberg, Germany. Jean-Louis Dasseux holds an MBA from the Ross School of Business of the University of Michigan, in the United States. He obtained his Master's in biochemistry at the University of Bordeaux II and his PhD in physical chemistry at the University of Bordeaux I. He has held postdoctoral positions at the Department of Chemistry of the University of Laval in Quebec, the Department of Physics at the University of Tennessee in Knoxville, Tennessee, and in the European Molecular Biology Laboratory at Heidelberg in Germany.
Cyrille Tupin, C.P.A.
Chief Financial Officer
Mr. Tupin was previously Audit Director of Sygnatures, the largest private audit and consulting company in Toulouse, France. He spent more than seven years at PriceWaterhouseCoopers with 2 years of international experience in Canada. He has worked on a number of high-profile business transactions, including the Alcan Group takeover bid for Pechiney and the consolidation audit of Pechiney for Alcan. Mr. Tupin has been a French C.P.A. since 2002.
Constance Keyserling, M.S.
Sr. Vice President, Clinical Development
Ms. Keyserling has over 25 years of global clinical development experience at Parke-Davis, Pfizer, Esperion, and QuatRx. She was previously Vice President of Development Operations at QuatRx. Prior to that, Ms. Keyserling was Senior Director of Operations at Esperion, where her responsibilities included clinical program design and management, clinical outsourcing, regulatory operations and SOP systems development. Constance Keyserling holds a Master's degree in biostatistics from Harvard University.